Navigation Links
Agent in Biological Technology

VisEn Launches Next-Generation Fast ('Fluorescence Activatible Sensor Technology') Agent Platform for Expanded Performance in Imaging Disease Biomarkers In Vivo

MMPSense(TM) 750 FAST is Presented at AACR 100th Annual Meeting BEDFORD, Mass., April 20 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the introduction of its new FAST ("Fluorescent Activatible Sensor Technolog...

CorVel Announces MSA Agent Services

IRVINE, Calif., Nov. 21 /PRNewswire-FirstCall/ -- CorVel Corporation (Nasdaq: CRVL ) announced today plans to provide "agent" services under the new Medicare legislation requiring expanded reporting for insurers, third party administrators and employers. The Company currently provides Medicare ...

Exposure to Agent Orange linked to prostate cancer in Vietnam veterans

(SACRAMENTO, Calif.) UC Davis Cancer Center physicians today released results of research showing that Vietnam War veterans exposed to Agent Orange have greatly increased risks of prostate cancer and even greater risks of getting the most aggressive form of the disease as compared to those who we...

Onyx Pharmaceuticals Licenses Rights to Novel Targeted Oncology Agent From BTG International

BGC 945 Builds Upon a Proven Class of Drugs With Greater Tumor Selectivity EMERYVILLE, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX ) today announced that it has in-licensed a novel targeted oncology compound, BGC 945, from BTG International Limited based i...

FDA Continues Review of Takeda's New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes

OSAKA, Japan, Oct. 10 /PRNewswire/ -- Takeda Pharmaceutical Company Limited ("Takeda") today announced that Takeda Global Research and Development Center, Inc., a wholly owned United States (U.S.) subsidiary, received notification that the U.S. Food and Drug Administration (FDA) will not be ab...

Exposure to Agent Orange linked to prostate cancer in Vietnam veterans

(SACRAMENTO, Calif.) UC Davis Cancer Center physicians today released results of research showing that Vietnam War veterans exposed to Agent Orange have greatly increased risks of prostate cancer and even greater risks of getting the most aggressive form of the disease as compared to those who we...

China-Biotics, Inc. Announces Appointment of New Transfer Agent Effective August 15, 2008

SHANGHAI, China, July 15 /Xinhua-PRNewswire-FirstCall/ -- China-Biotics, Inc. (OTC Bulletin Board: CHBT) ("China-Biotics," "the Company"), a leading Chinese firm specializing in the manufacture, research, development, marketing and distribution of probiotics products, today announced the appoi...

Astellas Launches Lexiscan(TM) (Regadenoson) Injection for Use as a Pharmacologic Stress Agent in Radionuclide Myocardial Perfusion Imaging (MPI)

-First A2A Adenosine Receptor Agonist Approved for Use in Identifying Coronary Artery Disease- DEERFIELD, Ill., June 24 /PRNewswire/ -- Astellas Pharma US, Inc. today announced the commercial availability of Lexiscan(TM) (regadenoson) injection, an A2A adenosine recepto...

Novel Investigational Regimen Combining Radiation Enhancing Agent With Ibritumomab Tiuxetan (Zevalin(R)) Produces High Rate of Complete Responses in Patients With Rituximab-Refractory Follicular Non-Hodgkin's Lymphoma

Results of phase I/II study highlighted in oral presentation at conference on malignant lymphoma LUGANO, Switzerland, June 5 /PRNewswire-FirstCall/ -- At the 10th International Conference on Malignant Lymphoma in Lugano, Switzerland data were presented from a phase I/II ...

Awareness of Genzyme's Renvela(R) (Sevelamer Carbonate) is High, Although Uptake of this New Phosphate Binding Agent has Been Slower than Nephrologists and Renal Dietitians Initially Expected

EXTON, Pa., May 23 /PRNewswire/ -- BioTrends Research Group, Inc. released Wave 1 of its LaunchTrends(TM): Renvela report, the second in a multi-phase syndicated market research project tracking the launch of Renvela from baseline awareness through the first six months of product availability....

CryoLife to Distribute FDA-approved Hemostatic Agent Under Private Label

ATLANTA, April 17 /PRNewswire-FirstCall/ -- CryoLife, Inc. (NYSE: CRY ), a biomaterials, medical device and tissue processing company, announced today that it has signed an exclusive three-year agreement with Minneapolis-based Medafor, Inc. Under terms of the agreement CryoLife will distribut...

Sumitomo Corporation of America Named Exclusive Distribution and Sales Agent for Chiral Quest

- Faster delivery, efficient supply chain, and reduced cost for pharmaceutical manufacturers NEW YORK, April 14 /PRNewswire/ -- Sumitomo Corporation of America (SCOA) has reached an agreement with Chiral Quest, Inc., a manufacturer and developer of chiral products usin...

Microfluidic Systems to Show Automated Biological Agent Detection Technology to U.S. House of Representatives

FREMONT, Calif., March 28 /PRNewswire/ -- Microfluidic Systems (MFSI), along with its manufacturing partner, United Technology's Hamilton Sundstrand Corporation, have been invited to attend the U.S. House of Representatives Committee on Homeland Security's Technology Fair on Detecting and Resp...

VisEn Launches New Cat-K FAST(TM) Fluorescence Molecular Imaging Agent

BEDFORD, Mass., July 7 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new Cat-K FAST (TM) imaging agent for measuring and monitoring Cathepsin K activity associated with disease progr...

UTSA/UTHSCSA publish results on bio-threat agent

San Antonio (June 30, 2008) Researchers at The University of Texas at San Antonio (UTSA) South Texas Center for Emerging Infectious Diseases and The University of Texas Health Science Center at San Antonio (UTHSCSA) have identified a cell type believed to play a role in controlling the early infe...

VisEn Announces Commercial Launch of IntegriSenseTM Fluorescence Molecular Imaging Agent

- First Product Developed from the VisEn-Merck & Co., Inc. Biomarker Imaging Program - - Expands VisEn's Leading Fluorescence Molecular Imaging Agent Portfolio and Broadens Applications in Key Areas of Disease Research and Drug Development - BEDFORD, Mass., Aug. 19 /PRNewswire/ -- VisEn Me...

UTSA/UTHSCSA publish results on bio-threat agent

San Antonio (June 30, 2008) Researchers at The University of Texas at San Antonio (UTSA) South Texas Center for Emerging Infectious Diseases and The University of Texas Health Science Center at San Antonio (UTHSCSA) have identified a cell type believed to play a role in controlling the early infe...

UTSA/UTHSCSA publish results on bio-threat agent

San Antonio (June 30, 2008) Researchers at The University of Texas at San Antonio (UTSA) South Texas Center for Emerging Infectious Diseases and The University of Texas Health Science Center at San Antonio (UTHSCSA) have identified a cell type believed to play a role in controlling the early infe...

Sangart, Inc. Completes Enrollment in Second Phase III Study of Hemospan, a Novel Oxygen Transport Agent

SAN DIEGO, May 19 /PRNewswire/ -- Sangart, Inc., a privately held biopharmaceutical company focused on the research, development and commercialization of therapeutic oxygen transport agents today announced that it has completed enrollment in the second Phase III trial of its lead product, Hemo...

ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent

Transfer Paves the Way for the Phase III Clinical Development and Commercialization of THR-100 in Developing Countries LEUVEN, Belgium, September 4 /PRNewswire/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular disease, today announced the su...

Cancer-fighting agent heads for clinical trials

Wauwatosa, Wis. - Now that Christopher Chitambar, a physician researcher at the Medical College of Wisconsin Cancer Center, has found that a gallium compound might be an effective anti-tumor agent, it's time for the test. If the compound is found to be safe and effective in forthcoming clini...

Choose the Right Transfection Agent for Your RNAi Experiment

The success of any RNA interference experiment depends on the efficient delivery of siRNA or siRNA expression vehicles (plasmids, PCR fragments) into cells. Many researchers use cationic liposomal and polyamine based ...

GE begins human trials for cancer detection agent

Madison, Wis. - Medical imaging technology provider GE Healthcare announced it has begun clinical trials of a new molecular imaging agent for the detection of cancer. The agent, which uses positron emission tomography (PET), is designed to track the process of angiogenesis, or the formation ...

NeurogesX Reports Second Quarter 2009 Results

...uded a short-term Qutenza study (Study C123) to determine whether an FDA-approved topical anesthetic would provide similar tolerability to the topical agent used as a pretreatment in the clinical development program. The study, conducted in patients with PHN, showed a mean duration of patch application of ...

Data Published in Cell Stem Cell Demonstrates Potent Anti-Cancer Activity for OncoMed Pharmaceuticals' Lead Antibody

...ents versus chemotherapy alone on the frequency of cancer stem cells in treated tumors. Results demonstrate that treatment with OMP-21M18 as a single agent or in combination with standard chemotherapeutic agents significantly decreases the ratio of cancer stem cells found in colon and breast tumors. Nota...

Keryx Biopharmaceuticals, Inc. Announces Second Quarter 2009 Financial Results

...RX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signa...ical efficacy in numerous adult and pediatric tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number o...

Exciton Technologies receives FDA approval to market exSALT(TM)

...T(TM) ---------------- Silver has powerful antimicrobial properties. In the proper chemical form, it is proven as a highly effective wound-care agent with important benefits for promoting healing and preventing infection. Exciton's exSALT(TM) antimicrobial technology uses a patented chemical deposit...

ADVENTRX Pharmaceuticals Announces Financing

.... Rodman & Renshaw, LLC, a wholly owned subsidiary of Rodman & Renshaw Capital Group, Inc. (Nasdaq: RODM ), acted as the exclusive placement agent for the transaction. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sal...

Pharmacyclics, Inc. Rights Offering Oversubscribed

... to 18,750,000 shares to up to 22,500,000 shares. The subscription agent has informed the Company that based on a preliminary tabulation, as of the ...d by us to a participating rights holder will be mailed by the subscription agent as promptly as practicable. The Company sold 22,500,000 shares of i...

Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2009 Financial Results on Thursday, August 6, 2009 at 8:30am EDT

...RX-0401 (perifosine), a novel, potentially first-in-class, oral anti-cancer agent that inhibits the phosphoinositide 3-kinase (PI3K)/Akt pathway, a key signa...ical efficacy in numerous adult and pediatric tumor types, both as a single agent and in combination with novel therapies. KRX-0401 also modulates a number o...

Sanofi-aventis U.S. Introduces BenzaClin(R) Carekit

... patients with acne who want to add a moisturizing agent to their skin care regimen. The BenzaClin ...ffer their patients who are seeking a moisturizing agent while using BenzaClin for their acne," says Brent ...(R) Viscontour(R) Serum is a cosmetic hydration agent that offers you a simple and convenient way of moi...

AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma

...th bortezomib (VELCADE(R)) and an immunomodulatory agent (REVLIMID(R) or THALIDOMID(R)) and previously trea...osine is a novel, first-in-class, oral anti-cancer agent that modulates several key signal transduction pat...f cancer cells. Perifosine has demonstrated single agent anti-tumor activity in Phase 1 and Phase 2 studies...

Purdue Pharmaceutical Products L.P. and Transcept Pharmaceuticals, Inc. Sign Exclusive Agreement to Commercialize Intermezzo(R) in the United States

...t at the time a patient awakens and has difficulty returning to sleep. Intermezzo ((R)) is a sublingual low dose formulation of zolpidem, the active agent most commonly prescribed in the United States for the treatment of insomnia. Intermezzo ((R)) uses approximately one-quarter to one-third of the dos...

Advanced Life Sciences Receives Complete Response Letter From FDA for Restanza(TM) (Cethromycin) in Community Acquired Pneumonia

... In parallel, the Company will continue to advance Restanza as a biodefense agent against anthrax, plague and tularemia. On June 2, 2009, the FDA Anti...at Restanza has significant therapeutic and commercial potential as a novel agent to combat CAP as well as other lethal pathogens that represent serious biot...

PharmAthene, Inc. Closes on $19.3 Million Private Placement of Convertible Notes and Common Stock Warrants

...will be exercisable for a period of five years beginning six months after the closing of the private placement. The Company did not engage a placement agent in connection with this transaction. About the Securities The securities that are being sold in the transaction have not been registered un...

Anadys Pharmaceuticals Receives FDA Clearance of Phase II Protocol to Study ANA598 in Combination With Interferon-Alpha and Ribavirin in HCV Patients

... from both cohorts during the first two quarters of 2010. "ANA598 has demonstrated potent antiviral activity and good tolerability as a single agent in Phase I, as well as preclinical properties indicative of likely synergy when used clinically in combination regimens," said Steve Worland, Ph.D., P...

Anadys Pharmaceuticals Reports Second Quarter 2009 Financial Results and Program Highlights

...with net proceeds of approximately $16.0 million, after deducting placement agent fees and estimated offering expenses. Proceeds from the transaction are be...ating potent antiviral activity and good tolerability of ANA598 as a single agent at all dose levels in a Phase Ib study in HCV patients were reported at the...

Senesco Technologies Enters Into Agreements For Additional $700,000 In Financing

...y closing conditions. There are no registration rights associated with the securities to be issued and sold in the private placement and no placement agent was used in connection with the private placement. Senesco primarily intends to utilize the net proceeds of these transactions to further adv...

Stemline Therapeutics CEO to Present at IBC's New Frontiers in Cancer Drug Development Conference

...erleukin-3 receptor present on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells. SL-401 has demonstrated single agent anti-tumor activity at tolerable doses in a multi-center Phase I human clinical trial. Stemline is also developing a portfolio of biological and small...

Sunesis Reports Financial Results for the Second Quarter 2009

...of VorEloxin in AmL) is a Phase 2 dose regimen optimization study of single agent voreloxin in newly diagnosed elderly AML patients who are unlikely to benef... Phase 2. Updated clinical data from the Phase 2 study of single agent voreloxin in women with platinum-resistant ovarian cancer were also present...
Other Tags
(Date:11/3/2014)... Research and Markets has announced the addition of a ... to their offering. This report describes ... started to play an important role in the practice of ... bone marrow transplants. Role of cells in drug discovery is ... of medical practice. Stem cells are discussed in ...
(Date:11/2/2014)... month,s issue of Physics World , James Dacey ... "valley of death" to take their innovations from the ... the gruelling challenge facing all start-up companies as they ... physicists because of two main factors: physics-based inventions are ... often turn out to be a lot more complicated ...
(Date:10/31/2014)... received two major government grants totaling nearly $28 million. ... to continue two major foci of study, one involving ... precision medicine. , The first, a combined grant from ... National Institute for Mental Health for $16.5 million, will ... CEGS. , The second grant, for $11.3 million, is ...
Breaking Biology News(10 mins):Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 2Global Cell Therapy - Technologies, Markets and Companies: 2014 Report 3The 'valley of death' facing physics start-ups 2Transforming 'big data' into knowledge 2Transforming 'big data' into knowledge 3
(Date:11/18/2014)... 18, 2014 A+ Secure Packaging, ... nutraceutical, dietary supplements and more, announced today that ... Good Manufacturing Practices (GMP) Registration for dietary supplements ... from NSF International verifies the A+ Secure Packaging ... compliance requirements of its clients by demonstrating the ...
(Date:11/18/2014)... Newport Beach, CA (PRWEB) November 18, 2014 ... settle into new routines, many people look at fall ... the holidays. Dr. Kevin Sadati , Orange County ... at this Newport Beach practice. At the Gallery ... his patients taking advantage of his non-invasive cosmetic surgery ...
(Date:11/18/2014)... Haelle HealthDay Reporter MONDAY, ... experience a severe abusive head trauma before the age of ... new study. In addition, among those who survive ... the study found. Abusive head trauma includes shaken baby ... suffers head injuries, according to background information in the study. ...
(Date:11/18/2014)... HealthDay Reporter , MONDAY, Nov. 17, ... not have significant heart-health benefits for older people, new ... than 14,000 Japanese people aged 60 to 85, found ... attacks and strokes between people who took aspirin and ... prevention with daily low-dose aspirin does not reduce the ...
(Date:11/18/2014)... Dennis Thompson HealthDay ... Heart attack and stroke patients can safely take aspirin combined ... blood-thinning combination won,t increase a patient,s risk of early death, ... meeting of the American Heart Association in Chicago. The report ... . Analysis of data from more than a dozen ...
Breaking Medicine News(10 mins):Health News:A+ Secure Packaging, LLC Earns NSF International Good Manufacturing Practices (GMP) Registration for Dietary Supplements and Certification for Sport 2Health News:Orange County Facial Plastic Surgeon, Dr. Kevin Sadati Observes a New Trend of Non-invasive Cosmetic Surgery Procedures Becoming Increasingly Popular This Fall 2Health News:Orange County Facial Plastic Surgeon, Dr. Kevin Sadati Observes a New Trend of Non-invasive Cosmetic Surgery Procedures Becoming Increasingly Popular This Fall 3Health News:Head Trauma in Abused Babies, Toddlers Can Have Lifelong Impact 2Health News:Head Trauma in Abused Babies, Toddlers Can Have Lifelong Impact 3Health News:Head Trauma in Abused Babies, Toddlers Can Have Lifelong Impact 4Health News:Daily Aspirin Fails to Help Older Hearts in Japanese Study 2Health News:Daily Aspirin Fails to Help Older Hearts in Japanese Study 3Health News:Long-Term Use of Aspirin Plus Blood Thinner Is Safe: Study 2Health News:Long-Term Use of Aspirin Plus Blood Thinner Is Safe: Study 3
Other Contents